January 2022 DAIDS Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Fiscal Year (FY) 2023 Concepts

FY 2023 Small Business Innovation Research (SBIR) Contract Solicitation Topics

Notice of Special Interest (NOSI)—Towards Developing a Cure for HBV in HIV/HBV Co-Infection

For the published notice of special interest, check the April 29, 2022 Guide announcement, Notice of Special Interest (NOSI)—towards Developing a Cure for HBV in HIV/HBV Co-Infection.

Notice of Special Interest (NOSI)—Next Generation Multipurpose Prevention Technologies

For the published program announcement with special receipt, referral, or review considerations, check the May 10, 2023 Guide announcement, Next Generation Multipurpose Prevention Technologies (NGM) (R01, Clinical Trial Optional).

Notice of Special Interest (NOSI)—Sustained Release of Antivirals for Treatment or Prevention (SRATP)

For the published notice of special interest, check the April 29, 2022 Guide notice, Notice of Special Interest (NOSI)—Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP).

Notice of Special Interest (NOSI)—Transgender People—Immunity, Prevention, and Treatment of HIV and STIs

For the published program announcement with special receipt, referral, or review considerations, check the May 10, 2022 Guide announcement, Transgender People—Immunity, Prevention, and Treatment of HIV and STIs (R21, Clinical Trial Not Allowed).

Notice of Special Interest (NOSI)—Identifying Immune Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection

For the published program announcement with special receipt, referral, or review considerations, check the August 9, 2022 Guide announcement, Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01, Clinical Trial Not Allowed).

Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program

For the published program announcement with special receipt, referral, or review considerations, check the May 27, 2022 Guide announcement, Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01, Clinical Trial Not Allowed).

Development of a Simian Immunodeficiency Virus (SIV) and Simian Human Immunodeficiency Virus (SHIV) Database

For the published request for proposals, check the August 8, 2022 solicitation, A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals.

Point-of-Care HIV Viral Load and Drug Adherence Assays To Accelerate “Ending the HIV Epidemic (EHE)”

For the published request for proposals, check the August 8, 2022 solicitation, A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals.

Development of Assays To Differentiate HIV Infection From Seropositivity Induced by HIV Vaccines

For the published request for proposals, check the August 8, 2022 solicitation, A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals.

Content last reviewed on